Please enable JavaScript to continue using this application.

Compare $AVBP vs $ODTX | Chartloom

Compare

$AVBP vs $ODTX

ArriVent BioPharma Inc · Odyssey Therapeutics Inc

AVBP

ArriVent BioPharma Inc

ODTX

Odyssey Therapeutics Inc

Compare $AVBP vs $ODTX

Comparing ArriVent BioPharma Inc and Odyssey Therapeutics Inc

AVBPArriVent BioPharma Inc

ODTXOdyssey Therapeutics Inc

AVBPArriVent BioPharma Inc

Market cap

$779M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

18.53x

Rev growth (TTM)

—

YTD performance

-19.6%

52W performance

-19.6%

FCF yield

-19.0%

ODTXOdyssey Therapeutics Inc

Market cap

$913M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-19.0%

YTD performance

15.7%

52W performance

15.7%

FCF yield

-4.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVBP

ODTX

Detailed metrics comparison

AVBP

ArriVent BioPharma Inc

ODTX

Odyssey Therapeutics Inc

Market Cap

AVBP$779M

ODTX$913M

Enterprise Value

AVBP$624M

ODTX$831M

Price

AVBP$16.73

ODTX$19.00

P/E Ratio

AVBPN/A

ODTXN/A

P/S Ratio

AVBP0.00x

ODTX306.64x

EV/Sales

AVBP0.00x

ODTX279.08x

EV/EBITDA

AVBP0.00x

ODTX0.00x

P/B Ratio

AVBP3.80x

ODTX2.36x

P/FCF Ratio

AVBPN/A

ODTXN/A

EV/FCF

AVBP-4.22x

ODTX-21.89x

PEG Ratio

AVBPN/A

ODTXN/A

Forward P/E (NTM)

AVBPN/A

ODTXN/A

Forward P/S (NTM)

AVBP18.53x

ODTXN/A

Revenue (TTM)

AVBP$0

ODTX$3M

Revenue Growth (YoY)

AVBPN/A

ODTX-19.0%

Forward Rev Growth

AVBP244.4%

ODTX410.3%

Gross Margin (TTM)

AVBP0.0%

ODTX0.0%

Operating Margin (TTM)

AVBP0.0%

ODTX0.0%

EBITDA Margin (TTM)

AVBP0.0%

ODTX-3193.4%

Net Margin (TTM)

AVBP0.0%

ODTX-8054.3%

FCF Margin (TTM)

AVBPN/A

ODTX-1275.0%

Net Income (TTM)

AVBP$-164M

ODTX$-240M

FCF (TTM)

AVBP$-148M

ODTX$-38M

EPS (TTM)

AVBP-$3.44

ODTX-$7.92

ROE (TTM)

AVBP-5026.0%

ODTX-3030.0%

ROA (TTM)

AVBP-4666.0%

ODTX-2554.0%

ROIC (TTM)

AVBP-5026.0%

ODTX-3030.0%

Cash

AVBP$155M

ODTX$82M

Debt

AVBP$0

ODTX$0

Net Cash/Debt

AVBP$155M

ODTX$82M

Current Ratio (TTM)

AVBP14.16x

ODTX11.36x

Quick Ratio (TTM)

AVBP14.14x

ODTX10.98x

Debt/Equity (TTM)

AVBP0.00x

ODTX0.00x

Debt/Assets (TTM)

AVBP0.0%

ODTX0.0%

Interest Coverage (TTM)

AVBPN/A

ODTXN/A

Net Debt/EBITDA (TTM)

AVBP0.00x

ODTX0.00x

Beta

AVBP1.42

ODTX-0.23

52W Performance

AVBP-19.6%

ODTX15.7%

YTD Performance

AVBP-19.6%

ODTX15.7%

% from 52W High

AVBP-53.3%

ODTX-34.6%

% from 52W Low

AVBP47.3%

ODTX25.8%

Asset Turnover (TTM)

AVBP0.00x

ODTX0.00x

FCF Yield (TTM)

AVBP-19.0%

ODTX-4.2%

Earnings Yield (TTM)

AVBP-21.0%

ODTX-26.3%

Dividend Yield (TTM)

AVBPN/A

ODTXN/A

Rule of 40

AVBP0.0

ODTX-1,294.1

EV/GP/RG

AVBPN/A

ODTXN/A

Ticker research

View AVBP research View ODTX research

Metric	AVBP ArriVent BioPharma Inc	ODTX Odyssey Therapeutics Inc
Market & Valuation
Market Cap	$779M	$913M
Enterprise Value	$624M	$831M
Price	$16.73	$19.00
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	306.64x
EV/Sales	0.00x	279.08x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.80x	2.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.22x	-21.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	18.53x	N/A
Revenue & Growth
Revenue (TTM)	$0	$3M
Revenue Growth (YoY)	N/A	-19.0%
Forward Rev Growth	244.4%	410.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-3193.4%
Net Margin (TTM)	0.0%	-8054.3%
FCF Margin (TTM)	N/A	-1275.0%
Net Income (TTM)	$-164M	$-240M
FCF (TTM)	$-148M	$-38M
EPS (TTM)	-$3.44	-$7.92
ROE (TTM)	-5026.0%	-3030.0%
ROA (TTM)	-4666.0%	-2554.0%
ROIC (TTM)	-5026.0%	-3030.0%
Financial Health
Cash	$155M	$82M
Debt	$0	$0
Net Cash/Debt	$155M	$82M
Current Ratio (TTM)	14.16x	11.36x
Quick Ratio (TTM)	14.14x	10.98x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.42	-0.23
52W Performance	-19.6%	15.7%
YTD Performance	-19.6%	15.7%
% from 52W High	-53.3%	-34.6%
% from 52W Low	47.3%	25.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-19.0%	-4.2%
Earnings Yield (TTM)	-21.0%	-26.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,294.1
EV/GP/RG	N/A	N/A
Ticker research	View AVBP research	View ODTX research

Valuation

P/S Ratio

AVBP

0.00x

ODTX

306.64x

EV/FCF

ODTX

-21.89x

AVBP

-4.22x

Growth & revenue

Revenue Growth TTM

ODTX

-19.0%

Forward Revenue Growth

ODTX

410.3%

AVBP

244.4%

Profitability & performance

Gross Margin

AVBP

0.0%

ODTX

0.0%

ROE

ODTX

-3030.0%

AVBP

-5026.0%

FCF Yield %

ODTX

-4.2%

AVBP

-19.0%

52-Week Performance

ODTX

15.7%

AVBP

-19.6%

Detailed metrics comparison

AVBP

ArriVent BioPharma Inc

ODTX

Odyssey Therapeutics Inc

Market Cap

AVBP$779M

ODTX$913M

Enterprise Value

AVBP$624M

ODTX$831M

Price

AVBP$16.73

ODTX$19.00

P/E Ratio

AVBPN/A

ODTXN/A

P/S Ratio

AVBP0.00x

ODTX306.64x

EV/Sales

AVBP0.00x

ODTX279.08x

EV/EBITDA

AVBP0.00x

ODTX0.00x

P/B Ratio

AVBP3.80x

ODTX2.36x

P/FCF Ratio

AVBPN/A

ODTXN/A

EV/FCF

AVBP-4.22x

ODTX-21.89x

PEG Ratio

AVBPN/A

ODTXN/A

Forward P/E (NTM)

AVBPN/A

ODTXN/A

Forward P/S (NTM)

AVBP18.53x

ODTXN/A

Revenue (TTM)

AVBP$0

ODTX$3M

Revenue Growth (YoY)

AVBPN/A

ODTX-19.0%

Forward Rev Growth

AVBP244.4%

ODTX410.3%

Gross Margin (TTM)

AVBP0.0%

ODTX0.0%

Operating Margin (TTM)

AVBP0.0%

ODTX0.0%

EBITDA Margin (TTM)

AVBP0.0%

ODTX-3193.4%

Net Margin (TTM)

AVBP0.0%

ODTX-8054.3%

FCF Margin (TTM)

AVBPN/A

ODTX-1275.0%

Net Income (TTM)

AVBP$-164M

ODTX$-240M

FCF (TTM)

AVBP$-148M

ODTX$-38M

EPS (TTM)

AVBP-$3.44

ODTX-$7.92

ROE (TTM)

AVBP-5026.0%

ODTX-3030.0%

ROA (TTM)

AVBP-4666.0%

ODTX-2554.0%

ROIC (TTM)

AVBP-5026.0%

ODTX-3030.0%

Cash

AVBP$155M

ODTX$82M

Debt

AVBP$0

ODTX$0

Net Cash/Debt

AVBP$155M

ODTX$82M

Current Ratio (TTM)

AVBP14.16x

ODTX11.36x

Quick Ratio (TTM)

AVBP14.14x

ODTX10.98x

Debt/Equity (TTM)

AVBP0.00x

ODTX0.00x

Debt/Assets (TTM)

AVBP0.0%

ODTX0.0%

Interest Coverage (TTM)

AVBPN/A

ODTXN/A

Net Debt/EBITDA (TTM)

AVBP0.00x

ODTX0.00x

Beta

AVBP1.42

ODTX-0.23

52W Performance

AVBP-19.6%

ODTX15.7%

YTD Performance

AVBP-19.6%

ODTX15.7%

% from 52W High

AVBP-53.3%

ODTX-34.6%

% from 52W Low

AVBP47.3%

ODTX25.8%

Asset Turnover (TTM)

AVBP0.00x

ODTX0.00x

FCF Yield (TTM)

AVBP-19.0%

ODTX-4.2%

Earnings Yield (TTM)

AVBP-21.0%

ODTX-26.3%

Dividend Yield (TTM)

AVBPN/A

ODTXN/A

Rule of 40

AVBP0.0

ODTX-1,294.1

EV/GP/RG

AVBPN/A

ODTXN/A

Ticker research

View AVBP research View ODTX research

Metric	AVBP ArriVent BioPharma Inc	ODTX Odyssey Therapeutics Inc
Market & Valuation
Market Cap	$779M	$913M
Enterprise Value	$624M	$831M
Price	$16.73	$19.00
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	306.64x
EV/Sales	0.00x	279.08x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.80x	2.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.22x	-21.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	18.53x	N/A
Revenue & Growth
Revenue (TTM)	$0	$3M
Revenue Growth (YoY)	N/A	-19.0%
Forward Rev Growth	244.4%	410.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-3193.4%
Net Margin (TTM)	0.0%	-8054.3%
FCF Margin (TTM)	N/A	-1275.0%
Net Income (TTM)	$-164M	$-240M
FCF (TTM)	$-148M	$-38M
EPS (TTM)	-$3.44	-$7.92
ROE (TTM)	-5026.0%	-3030.0%
ROA (TTM)	-4666.0%	-2554.0%
ROIC (TTM)	-5026.0%	-3030.0%
Financial Health
Cash	$155M	$82M
Debt	$0	$0
Net Cash/Debt	$155M	$82M
Current Ratio (TTM)	14.16x	11.36x
Quick Ratio (TTM)	14.14x	10.98x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.42	-0.23
52W Performance	-19.6%	15.7%
YTD Performance	-19.6%	15.7%
% from 52W High	-53.3%	-34.6%
% from 52W Low	47.3%	25.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-19.0%	-4.2%
Earnings Yield (TTM)	-21.0%	-26.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,294.1
EV/GP/RG	N/A	N/A
Ticker research	View AVBP research	View ODTX research